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We	would	like	to	thank	Dr	Tomoyuki	Kawada	for	his	thoughtful	comments	on	our	recent	
article1.	
In	the	main	analysis	of	the	CAROSS	trial2,	a	smoking	cessation	trial	assessing	ultrasonographic	
visualisation	of	carotid	plaques	as	a	potential	motivational	intervention,	we	found	a	smoking	
cessation	rate	of	20%	after	1	year,	in	both	the	intervention	and	control	arms2,	which	is	in	line	
with	other	smoking	cessation	trials3.	Our	recent	article	is	a	secondary	analysis	of	the	
intervention	group	(n=267	at	inclusion)	with	an	extended	follow-up	of	3	years,	including	a	
carotid	ultrasound.	
	
We	agree	with	Dr	Kawada	that	our	study	does	not	have	enough	statistical	power	to	
demonstrate	a	definite	influence	of	smoking	cessation	and/or	relapse	on	carotid	intima-
media	thickness	(CIMT)	progression.	A	higher	number	of	participants	as	well	as	a	longer	
follow-up	would	be	needed	to	demonstrate	its	impact	on	CIMT.	Therefore,	restricting	our	
analysis	to	data	between	the	1-year	and	3-year	time	points	(i.e.	2	years’	worth	of	data,	n=208)	
instead	of	the	complete	dataset	over	3	years	of	follow-up	(n=276)	would	have	led	to	even	less	
statistical	power	and	relevant	information.	
	
We	used	carotid	ultrasound	in	the	CAROSS	trial2	to	let	smokers	visualize	the	impact	of	
cigarette	smoking	on	their	arteries.	We	did	not	aim	at	assessing	the	nature	of	carotid	plaques	
but	focused	on	their	presence	vs.	absence,	using	the	commonly	accepted	method	of	the	
Rotterdam	Study4	and	recommended	by	the	US	Task	Force5.		Additionally,	we	measured	CIMT	
at	one	specific	site	within	the	carotid	arteries6	to	obtain	a	precise	outcome	for	detection	of	
more	subtle	changes	during	follow-up.	
	We	found	that	baseline	fasting	blood	glucose	seemed	to	have	a	significant	negative	
association	with	3-year	CIMT	progression	in	our	study	(p=0.03),	but	it	was	likely	a	chance	
finding,	as	we	found	no	association	with	baseline	and	1-year	CIMT.	Furthermore,	no	time-
dependent	follow-up	of	fasting	blood	glucose	was	implemented.		
	
In	summary,	our	analysis	including	data	of	the	complete	3-year	follow-up	allowed	us	to	
identify	increased	blood	pressure	as	a	risk	factor	on	CIMT	progression	in	smokers.	
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